X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SUN PHARMACEUTICAL INDUSTRIES LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

SUN PHARMACEUTICAL INDUSTRIES LIMITED  (SUNP)


Here is the latest financial fact sheet of Sun Pharma. For more details, see the Sun Pharma quarterly results and Sun Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
sun pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 703.3       No. of shares m 2,406.75
    Mkt Cap Rs m 1,692,669       % ch % -0.1
    Vol '000 157.7       % ch week % -0.5
    P/E X 21.9       % ch 1-mth % 4.2
    P/CF X 24.7       % ch 12-mth % -13.3
    EPS (TTM) Rs 32.0       52 week H/L Rs 854.5/572.4
(As on Mar 24, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs5948486531,0741,201 
Low Rs423554493570706 
Sales per share (Unadj.) Rs77.4109.177.6132.3117.5 
Earnings per share (Unadj.) Rs25.728.815.221.919.6 
Diluted earnings per shareRs11.012.413.118.919.6 
Cash flow per share (Unadj.) Rs28.532.117.127.723.8 
Dividends per share (Unadj.) Rs4.255.001.503.001.00 
Adj. dividends per shareRs1.832.151.292.581.00 
Dividend yield (eoy) %0.80.70.30.40.1 
Book value per share (Unadj.) Rs118.2144.789.4123.7130.5 
Adj. book value per shareRs50.862.377.0106.5130.5 
Shares outstanding (eoy) m1,035.581,035.582,071.162,071.162,406.60 
Bonus/Rights/Conversions  --B1:1-- 
Price / Sales ratio x6.66.47.46.28.1 
Avg P/E ratio x19.824.337.837.548.7 
P/CF ratio (eoy) x17.921.933.429.740.1 
Price / Book Value ratio x4.34.86.46.67.3 
Dividend payout %16.617.49.913.75.1 
Avg Mkt Cap Rs m526,592725,9421,186,7751,703,0112,294,813 
No. of employees `00012.614.014.0NA14.7 
Total wages/salary Rs m11,87715,34520,74445,02647,971 
Avg. sales/employee Rs Th6,364.78,071.311,486.0NM19,169.8 
Avg. wages/employee Rs Th942.61,096.11,481.7NM3,253.0 
Avg. net profit/employee Rs Th2,108.52,130.82,243.9NM3,197.9 
  INCOME DATA
Net Sales Rs m80,195112,999160,804273,920282,697 
Other income Rs m2,3002,7632,6475,4776,170 
Total revenues Rs m82,495115,761163,451279,397288,867 
Gross profit Rs m32,04348,96272,87378,66783,239 
Depreciation Rs m2,9123,3624,09211,94710,135 
Interest Rs m2824324425,7904,769 
Profit before tax Rs m31,15047,93270,98666,40774,505 
Minority Interest Rs m-3,855-4,863-7,375-9,363-11,126 
Prior Period Items Rs m000-126-19 
Extraordinary Inc (Exp) Rs m2,404-4,783-25,174-2,378-6,852 
Tax Rs m3,1328,4567,0229,1479,349 
Profit after tax Rs m26,56729,83131,41545,39447,159 
Gross profit margin %40.043.345.328.729.4 
Effective tax rate %10.117.69.913.812.5 
Net profit margin %33.126.419.516.616.7 
  BALANCE SHEET DATA
Current assets Rs m102,934115,030186,865289,158308,646 
Current liabilities Rs m26,18528,41359,896161,468132,477 
Net working cap to sales %95.776.779.046.662.3 
Current ratio x3.94.03.11.82.3 
Inventory Days Days9583717683 
Debtors Days Days9578506888 
Net fixed assets Rs m32,74250,77158,242110,201133,606 
Share capital Rs m1,0361,0362,0712,0712,407 
"Free" reserves Rs m112,503136,274163,019222,763266,909 
Net worth Rs m122,358149,897185,250256,232314,042 
Long term debt Rs m1,5541,15348713,68431,167 
Total assets Rs m164,740205,827293,708487,985542,196 
Interest coverage x111.5112.1161.612.516.6 
Debt to equity ratio x0000.10.1 
Sales to assets ratio x0.50.50.50.60.5 
Return on assets %16.314.710.810.59.6 
Return on equity %21.719.917.017.715.0 
Return on capital %24.225.620.922.417.8 
Exports to sales %18.217.014.116.914.0 
Imports to sales %6.04.73.64.53.1 
Exports (fob) Rs m14,62819,23822,71346,23539,572 
Imports (cif) Rs m4,8195,3535,77912,2298,882 
Fx inflow Rs m14,64619,61523,16848,70642,171 
Fx outflow Rs m6,3697,87712,62925,56421,583 
Net fx Rs m8,27711,73910,53923,14220,588 
  CASH FLOW
From Operations Rs m 22,345 33,566 39,592 56,157 67,694 
From Investments Rs m -8,627 -26,351 -23,668 -28,657 -44,549 
From Financial Activity Rs m -5,444 -6,650 5,066 -11,865 -19,243 
Net Cashflow Rs m 8,274 565 20,990 15,635 3,902 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for sun pharmaceutical industries limited

 Share Holding
Indian Promoters : 63.7%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 5.1%
FIIs : 23.0%
ADR/GDR : 0.0%
Free float : 8.3%
Shareholders : 133,026
Pledged promoter(s) holding : 0.5%
 Company Information
Top
    REGD OFF: Sun Pharma Advanced Research Centre, Tandalja, Vadodara - 390 020
    E-MAIL: sunil.ajmera@sunpharma.com     WEB: www.sunpharma.com
    TELEPHONE: (022) 6696 9696     FAX: (022) 2821 2010
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Cmpd., LBS Marg, Mumbai-78
    AUDITOR: Deloitte Haskins & Sells
CHM: Israel Makov COMP SEC: Sunil R. Ajmera YEAR OF INC: 1993 BSE CODE: 524715 FV (Rs): 1 DIV YIELD (%): 0.1

More pharmaceuticals Company Fact Sheets:   CADILA HEALTHCAREAMAR REMEDIESTTK HEALTHCAREELDER PHARMAALKEM LABORATORIES


Today's Market

Sensex Finishes Marginally Higher; Jaitley's Comments Boost Bank Stocks(Closing)

Indian share markets trimmed their early gains in the afternoon session to finish marginally higher. At the closing bell, the BSE Sensex stood higher by 89 points, while the NSE Nifty finished up by 22 points.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Sun Pharma: US Segment Shows Signs of Improvement (Quarterly Results Update - Detailed)

Sep 12, 2016

Sun Pharma has announced its 1QFY17 results. The company has reported 22.7% YoY growth in sales and a growth of 266% in the net profits. Here is our analysis of the results.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Doubled Your Money In D-Mart? Read This Before It's Too Late(Daily Profit Hunter)

Mar 22, 2017

Apurva breaks down the historic performance of initial public offerings in the context of D-Mart.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

4 Things To Watch Out For After Modi's Landslide Win In UP Polls(Outside View)

Mar 15, 2017

PersonalFN explains why you need to wary while investing in equities despite Modi's UP win.

More

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUN PHARMA

SUN PHARMA - TEVA PHARMA COMPARISON

Compare Company With Charts

COMPARE SUN PHARMA WITH

MARKET STATS